Document is current
Any future updates will be listed below
-
Authors
Bröckelmann, Paul J. https://orcid.org/0000-0001-9662-9900
- License Information
-
More Information
Article History
First Online: 10 March 2025
Competing interests
: P.J.B. is an advisor or consultant for Hexal, MSD, Need Inc, Stemline and Takeda; holds stock options in Need Inc; has received honoraria from AstraZeneca, BeiGene, BMS/Celgene, Lilly, Merck Sharp & Dohme, Need Inc, Stemline and Takeda; and his institution has received research funding from BeiGene, BMS, Merck Sharp & Dohme and Takeda (Inst). P.J.B. is an active member of the GHSG, which conducted the HD21 trial1, but not an author of either of the two articles primarily discussed herein1,2.
